dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Oaknin Benzaquen, Ana Mazaltob |
dc.contributor.author | Monk, Bradley J. |
dc.contributor.author | de Melo, Andreia Cristina |
dc.contributor.author | Kim, Yong-Man |
dc.contributor.author | Lisyanskaya, Alla |
dc.contributor.author | Vergote, Ignace |
dc.date.accessioned | 2022-10-19T11:39:58Z |
dc.date.available | 2022-10-19T11:39:58Z |
dc.date.issued | 2022-10 |
dc.identifier.citation | Oaknin A, Monk BJ, Vergote I, Cristina de Melo A, Kim Y-M, Lisyanskaya AS, et al. EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer. Eur J Cancer. 2022 Oct;174:299–309. |
dc.identifier.issn | 0959-8049 |
dc.identifier.uri | https://hdl.handle.net/11351/8320 |
dc.description | Quimioteràpia; Qualitat de vida; Símptomes |
dc.description.sponsorship | This work was supported by Regeneron Pharmaceuticals, Inc., and Sanofi. |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | European Journal of Cancer;174 |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Coll uterí - Càncer - Tractament |
dc.subject | Quimioteràpia combinada |
dc.subject | Pacients - Satisfacció |
dc.subject.mesh | Patient Reported Outcome Measures |
dc.subject.mesh | Uterine Cervical Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.title | EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.ejca.2022.03.016 |
dc.subject.decs | medidas de resultados percibidos por los pacientes |
dc.subject.decs | neoplasias del cuello uterino |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.relation.publishversion | https://doi.org/10.1016/j.ejca.2022.03.016 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Oaknin A] Gynaecologic Cancer Programme, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Monk BJ] Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona, Creighton University, Phoenix, AZ, USA. [Vergote I] Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, University Hospitals, KU Leuven, Leuven, Belgium. [Cristina de Melo A] Division of Clinical Research and Technological Development, Hospital Do Câncer II, Brazilian National Cancer Institute, Rio de Janeiro, Brazil. [Kim YM] Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan, Seoul, South Korea. [Lisyanskaya AS] St Petersburg State Budgetary Institution of Healthcare, St Petersburg, Russia |
dc.identifier.pmid | 35922251 |
dc.identifier.wos | 000856565300004 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |